___

• Adnane M, Meade KG, O’Farrelly C (2018). Cervico-vaginal mucus (CVM)–an accessible source of immunologically informative biomolecules. Veterinary Research Communications 42 (4): 255-263.
• Appidi T, Mudigunda SV, Kodandapani S, Rengan AK (2020). Development of label-free gold nanoparticle based rapid colorimetric assay for clinical/point-of-care screening of cervical cancer. Nanoscale Advances 2 (12): 5737-5745.
• Arbyn M, Verdoodt F, Snijders PJ, Verhoef, Suonio VM et al. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta- analysis. Lancet Oncology 15 (2): 172–183.
• Arbyn M, Weiderpass E, Bruni L et al. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health 8 (2): e191-e203.
• Bal MD (2014). Evaluation of Women Having Pap Smear Test by Health Belief Model Scale. Clinical and Experimental Health Sciences 4 (3): 133-138.
• Bandu R, Oh JW, Kim KP (2020). Mass spectrometry-based proteome profiling of extracellular vesicles and their roles in cancer biology. Experimental & Molecular Medicine 51 (3): 1-10.
• Belokrinitskaya T, Frolova N, Turanova O, Pletneva V, Paltseva T et al. (2019). Efficiency and acceptability of human papillomavirus detection on self-collected versus clinician-collected samples in vaginal discharge. European Journal of Obstetrics and Gynecology and Reproductive Biology (234): e161.
• Boers A, Bosgraaf RP, Van Leeuwen RW, Schuuring E, Heideman DAM et al. (2014). DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. British Journal of Cancer 111 (6): 1095.
• Borgdorff H, Gautam R, Armstrong SD, Xia D, Ndayisaba GF et al. (2016). Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunology 9 (3): 621.
• Boylan KL, Afiuni-Zadeh S, Geller MA, Hickey K, Griffin TJ et al. (2014). A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. Clinical Proteomics 11 (1): 30.
• Calis P, Yuce K, Basaran D, Salman C (2016). Assessment of cervicovaginal cancer antigen 125 levels: a preliminary study for endometrial cancer screening. Gynecol Obstet Invest 81 (6): 518–522.
• Canfell K. (2019). Towards the global elimination of cervical cancer Papillomavirus Research 8: 100170.
• Casado-Vela J, Rodriguez-Suarez E, Iloro I, Ametzazurra A, Alkorta N et al. (2009). Comprehensive proteomic analysis of human endometrial fluid aspirate. Journal of Proteome Research 8 (10): 4622-4632.
• Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG et al. (2002). Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA‐positive, cytologically negative women. Cancer: Interdisciplinary International Journal of the American Cancer Society 95 (10): 2145-2151.
• Chappell CA, Rohan LC, Moncla BJ, Wang L, Meyn L et al. (2014). The effects of reproductive hormones on the physical properties of cervicovaginal fluid. American Journal of Obstetrics and Gynecology 211 (3): 226-e1.
• Chen H, Liu K, Li Z, Wang P (2019). Point of care testing for infectious diseases. Clinica Chimica Acta 493: 138-147.
• Csősz É, Kalló G, Márkus B, Deák E, Csutak A et al. (2017). Quantitative body fluid proteomics in medicine - A focus on minimal invasiveness. Journal of Proteomics 153: 30-43.
• Devarapalli P, Labani S, Nagarjuna N, Panchal P, Asthana S (2018). Barriers affecting uptake of cervical cancer screening in low and middle income countries: A systematic review. Indian Journal of Cancer 55 (4): 318.
• Elovitz MA, Gajer P, Riis V, Brown AG, Humphrys MS et al. (2019). Cervicovaginal microbiota and local immune response modulate the risk of spontaneous preterm delivery. Nature Communications 10 (1): 1-8.
• Gutiérrez AL, Lindberg JH, Shevchenko G, Gustavsson I, Bergquist J et al. (2021). Identification of Candidate Protein Biomarkers for CIN2+ Lesions from Self-Sampled, Dried Cervico–Vaginal Fluid Using LC-MS/MS. Cancers 13 (11): 92.
• Hong S, Jung YM, Lee YE, Park Y, Kim YM et al. (2020). Complement and other immune-related factors in cervicovaginal fluid associated with intra-amniotic infection/inflammation and spontaneous preterm delivery in women with preterm labor. Archives of Gynecology and Obstetrics 1-9.
• Horgan RP, Kenny LC (2011). ‘Omic’technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist 13 (3): 189-195.
• Inan H, Wang S, Inci F, Baday M, Zangar R et al. (2017). Isolation, detection, and quantification of cancer biomarkers in HPVassociated malignancies. Scientific Reports 7 (1): 3322.
• Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E et al. (2007). Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infectious Agents and Cancer 2 (1): 1-10.
• Janssens PM (2017). Recognizing and differentiating uncommon body fluids: Considerations and tools for a proper practical approach. Clinica Chimica Acta 471: 6-11.
• Kindinger LM, MacIntyre DA, Lee YS, Marchesi JR, Smith A et al. (2016). Relationship between vaginal microbial dysbiosis, inflammation, and pregnancy outcomes in cervical cerclage. Science Translational Medicine 8 (350): 102.
• Koonmee S, Bychkov A, Shuangshoti S, Bhummichitra K, Himakhun W et al. (2017). False-negative rate of papanicolaou testing: a national survey from the Thai society of cytology. Acta Cytologica 61 (6): 434-440.
• Kulasingam V, Diamandis EP (2008). Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Reviews Clinical Oncology 5 (10): 588.
• Lam CT, Krieger MS, Gallagher JE, Asma B, Muasher LC et al. (2015). Design of a novel low cost point of care tampon (POCkeT) colposcope for use in resource limited settings. PloS one 10 (9). Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A et al. (2019). Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Scientific Reports 9 (1): 1-14.
• Malone C, Barnabas RV, Buist DS, Tiro JA, Winer RL (2020). Costeffectiveness studies of HPV self-sampling: A systematic review. Preventive Medicine 105953.
• Martínez-Rodríguez F, Limones-González JE, Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI et al. (2021). Understanding Cervical Cancer through Proteomics. Cells 10 (8): 1854.
• Maza M, Melendez M, Masch R, Alfaro K, Chacon A et al. (2018). Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. Preventive Medicine 114: 149-155.
• Mohammed SI, Ren W, Flowers L, Rajwa B, Chibwesha CJ et al. (2016). Point-of-care test for cervical cancer in LMICs. Oncotarget 7 (14): 18787.
• Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R et al. (2017). The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sexually Transmitted Infections 93 (1): 56-61.
• Othman NH, Mohamad FH (2014). Self-collection tools for routine cervical cancer screening: A review. Asian Pacific Organization for Cancer Prevention 15 (20): 8563-8569.
• Parry S, Leite R, Esplin MS, Bukowski R, Zhang H et al. (2020). Cervicovaginal fluid proteomic analysis to identify potential biomarkers for preterm birth. American Journal of Obstetrics and Gynecology 222 (5): 493-e1.
• Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P et al. (2009). Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions: A review of the literature. Papillomavirus Research 8: 100185.
• Peeling R, Mabey D (2010). Point-of-care tests for diagnosing infections in the developing world. Clinical Microbiology and Infection 16 (8): 1062-1069.
• Qin J, Saraiya M, Martinez G, Sawaya GF (2020). Prevalence of potentially unnecessary bimanual pelvic examinations and Papanicolaou tests among adolescent girls and young women aged 15-20 years in the United States. JAMA Internal Medicine 180 (2): 274-280.
• Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB et al. (2012). Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prevention Research 5 (5): 706-716.
• Ren W, Mohammed SI, Wereley S, Irudayaraj J (2019). Magnetic focus lateral flow sensor for detection of cervical cancer biomarkers. Analytical Chemistry 91 (4): 2876-2884.
• Riganelli L, Iebba V, Piccioni M, Illuminati I, Bonfiglio G et al. (2020). Structural variations of vaginal and endometrial microbiota: Hints on female infertility. Frontiers in Cellular and Infection Microbiology 10: 350.
• Rodriguez NM, Wong WS, Liu L, Dewar R, Klapperich CM (2016). A fully integrated paperfluidic molecular diagnostic chip for the extraction, amplification, and detection of nucleic acids from clinical samples. Lab on a Chip 16 (4): 753-763.
• Sangwa-Lugoma G, Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK et al. (2011). Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. Sexually Transmitted Diseases 38 (4): 308-315.
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007). Human papillomavirus and cervical cancer. The Lancet 370 (9590): 890-907.
• Shannon B, Yi TJ, Perusini S, Gajer P, Ma B et al. (2017). Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal immunology 10 (5): 1310-1319.
• Shaw JL, Smith CR, Diamandis EP (2007). Proteomic analysis of human cervico-vaginal fluid. Journal of Proteome Research 6: 2859–65.
• Shukair SA, Allen SA, Cianci GC, Stieh DJ, Anderson MR et al. (2013). Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunology 6 (2): 427- 434.
• Starodubtseva NL, Brzhozovzki AG, Bugrova AE, Kononikhin AS, Indeykina MI et al. (2019). Label‐free cervıcovagınal fluıd proteome profılıng reflects the cervıx neoplastıc transformatıon. Journal of Mass Spectrometry 54 (8): 693-703.
• Tang LJ, De SF, Odreman F, Venge P, Piva C et al. (2007). Proteomic analysis of human cervical-vaginal fluids. Journal of Proteome Research 6:2874–83.
• Tay A, Pavesi SR, Yazdi CT, Lim CT, Warkiani ME (2016). Advances in microfluidics in combating infectious diseases. Biotechnology Advances 34 (4): 404–421.
• Terzi H, Kale E, Kale A, Turkay U, Chong GO et al. (2015). New method: Are tumor markers in vaginal-washing fluid significant in the diagnosis of primary ovarian carcinoma. European Journal of Gynaecological Oncology (5): 560-563.
• Curlin M, Bursac D (2013). Cervical mucus: from biochemical structure to clinical implications. Frontiers in Bioscience 5: 507-515.
• Van Ostade X, Dom M, Tjalma W, Van Raemdonck G (2018). Candidate biomarkers in the cervical vaginal fluid for the (self- ) diagnosis of cervical precancer. Archives of Gynecology and Obstetrics 297 (2): 295-311.
• Van Raemdonck GA, Tjalma WA, Coen EP, Depuydt CE, Van Ostade XW (2014). Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One 9 (9): e106488.
• Vasconcelos CTM, Cunha DDFF, Coelho CF, Pinheiro AKB, Sawada NO (2014). Factors related to failure to attend the consultation to receive the results of the Pap smear test. Revista LatinoAmericana de Enfermagem 22: 401-407.
• Vashist SK, Luong JH (2019). An overview of point-of-care technologies enabling next-generation healthcare monitoring and management. Point-of-Care Technologies Enabling NextGeneration Healthcare Monitoring and Management 1-25.
• Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM (2005). Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. The Journal of Immunology 175 (11): 7560-7567.
• Vicente-Muñoz S, Cobo T, Puchades-Carrasco L, Sánchez-García AB, Agustí N et al. (2020). Vaginal metabolome: towards a minimally invasive diagnosis of microbial invasion of the amniotic cavity in women with preterm labor. Scientific Reports 10 (1): 1-9.
• Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J et al. (2014). Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. European Journal of Clinical Microbiology & Infectious Diseases 33 (11): 2005-2014.
• Waldman RH, Cruz JM, Row DS (1972). Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. Clinical and Experimental Immunology 10 (3): 427.
• Warren AD, Kwong GA, Wood DK, Lin KY, Bhatia SN (2014). Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proceedings of the National Academy of Sciences 111 (10): 3671-3676.
• Wikström I, Lindell M, Sanner K, Wilander E (2011). Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. British Journal of Cancer 105 (3): 337.
• Wilson MS, Nie W (2006). Multiplex measurement of seven tumor markers using an electrochemical protein chip. Analytical Chemistry 78 (18): 6476-6483.
• World Health Organization (2018). The Global Cancer Observatory, Cancer Fact Sheets: Cervix-uteri, 2018 [online]. Website https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervixuteri-fact-sheet.pdf , 2019 (Accessed 10 January 2020).
• Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW (2009). Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Science 7 (1): 17.
• Zegels G, Van Raemdonck GA, Tjalma WA, Van Ostade X (2007). Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome science 8 (1): 1-23.
• Zhang JJ, Cao XC, Zheng XY, Wang HY, Li YW (2018). Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer. Journal of International Medical Research 46 (3): 1033-1042.